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Abstract
MicroRNAs (miRNAs) are pervasively expressed and 
regulate most biological functions. They function by 
modulating transcriptional and translational programs 
and therefore they orchestrate both physiological and 
pathological processes, such as development, cell 
differentiation, proliferation, apoptosis and tumor growth. 
miRNAs work as small guide molecules in RNA silencing, 
by negatively regulating the expression of several genes 
both at mRNA and protein level, by degrading their mRNA 
target and/or by silencing translation. One of the most 
recent advances in the field is the comprehension of 
their role in oncogenesis. The number of miRNA genes 
is increasing and an alteration in the level of miRNAs is 
involved in the initiation, progression and metastases 
formation of several tumors. Some tumor types show a 
distinct miRNA signature that distinguishes them from 
normal tissues and from other cancer types. Genetic 
and biochemical evidence supports the essential role of 
miRNAs in tumor development. Although the abnormal 
expression of miRNAs in cancer cells is a widely accepted 
phenomenon, the cause of this dysregulation is still 
unknown. Here, we discuss the biogenesis of miRNAs, 
focusing on the mechanisms by which they regulate 
protein synthesis. In addition we debate on their role in 
cancer, highlighting their potential to become therapeutic 
targets.
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Core tip: MicroRNAs (miRNAs) are short non-coding 
RNAs (19-25 bp in length) which negatively regulate gene 
expression at the mRNA and protein level. By binding 
coding transcripts, miRNAs cause degradation or trans-
lation inhibition of their target genes and affect a multi-
tude of biological processes, such as proliferation and 
tumor growth. In this review we critically analyze the 
mechanism of action of miRNAs and their potential role 
in cancer, opening a window on future perspectives for 
their use as novel therapeutic targets.
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INTRODUCTION
Recent advances in transcriptome analysis and high-
throughput technologies highlighted an impressive com-
plexity in the RNA world. The most studied RNA regions 
are protein-coding genes, mRNAs, accounting for around 
1.5% of the human genome[1]. The importance of coding 
mRNAs is undisputable as they have been for years the 
building brick of experimental biology, culminating in the 
systematic deletion of coding genes in several species. 
Not less important are retrotransposons, specific genetic 
elements which are known to regulate gene expression[2,3]. 
Since RNA was identified as the crux of genetic regulation, 
the idea that it carries fundamental information has been 
extended to novel classes of RNA. More recently, the non-
protein coding portion of the genome gained attention 
due to its unexpected role in regulating development and 
disease[4]. Nowadays, most scientists agree in stating 
that transcription of the human genome is pervasive, 
therefore raising questions on the function of many un-
characterized RNAs. 
The discovery of non-coding RNAs (ncRNAs) has 
changed the way we look at the human genome and 
led the scientific world to characterize the different 
types of ncRNAs transcribed in human cells. Although 
there is not a clear delineation of ncRNA classes, they 
are usually classified, according to their nucleotides 
length, in three main groups: Short ncRNAs, mid-size 
ncRNAs and long ncRNAs[5]. Among short ncRNAs we 
can distinguish between microRNAs (miRNA) and piwi-
interacting RNAs (piRNAs), respectively 19-25 base 
pairs (bp) and 26-31 bp long. miRNAs are involved in 
the regulation of gene expression at the translational 
and stability level[6-8], while piRNAs are involved in DNA 
methylation and transposon repression[9-11]. Small 
nucleolar RNAs (60-300 bp) are part of mid-size RNAs 
and act as guides for rRNA modifications[12], Promoter 
Associated RNAs (22-200 bp) belong to the same group 
but their function is obscure[13]. Last but not least, long 
non-coding RNAs (lncRNAs) comprise all ncRNAs longer 
than 200 nucleotides and include the largest portion of 
the non-coding transcriptome[4]. lncRNAs are involved 
in several biological and pathological processes, such as 
genomic imprinting, telomere regulation, X-chromosome 
inactivation, development, stem cell pluripotency, 
immune regulation, cancer progression and in metastatic 
potential[14,15]. In particular, a subset of lncRNAs, the 
T-UCR, themselves target specific miRNAs. The binding 
between these lncRNAs and miRNAs prevents target 
transcription degradation determining an intricate co-
regulation between lncRNAs and miRNAs[16-18] and strictly 
linking these two different types of ncRNAs. It should 
be however stressed out that the definition of ncRNA 
relies mainly on bioinformatic tools that are likely to be 
challenged in the next future. In particular, open reading 
frames (ORF) shorter than 100 nucleotides and/or lacking 
a strong ATG consensus sequence for translational start 
are considered noncoding. In view of the emergence of 
alternative translational start sites[19], we may discover 
that at least some ncRNAs are indeed “coding” for small 
peptides.
The relevance of the non-coding transcriptome in 
the comprehension of human diseases is highlighted by 
the impressive number of ncRNAs that are abnormally 
expressed in cancer, in neurological and heart diseases 
or in immune disorders. In this context, short RNAs 
have attracted the attention of most researchers. Here, 
we focus on miRNA and on their role in translation 
regulation and cancer. In particular we zoom in the known 
mechanisms of miRNA-regulated translation, after a brief 
elucidation of their discovery and biogenesis. Finally, we 
account for the aberrant expression of miRNAs in cancer 
and for their therapeutical potential as new drugs.
miRNA: DISCOVERY AND BIOGENESIS 
A brief history
miRNAs are endogenous, non-coding single stranded 
RNAs of approximately 19-25 nucleotides in length, 
found both in animals and plants and involved in post 
transcriptional regulation[7,20]. Two decades ago the 
existence of miRNAs was obscure and the scientific 
community was focused largely on protein-coding genes. 
However in 1993 the discovery of the first small 
ncRNA lin-4, in C. elegans, has totally changed the 
scientists’ point of view[21]. At the time of the first dis-
coveries, two main questions were raised: (1) what 
is the role of lin-4; and (2) what is its mechanism of 
action? Genetic studies showed that lin-4 is one of the 
most relevant genes involved in the control of temporal 
development of larval stages[22,23]. Almost simultaneously, 
Lee and collaborators discovered that null mutations of 
the lin-14 gene were able to cause an opposite phenotype 
to null lin-4 mutations, suggesting that lin-4 could regulate 
lin-14[23,24]. How was this regulation taking place? Several 
groups unequivocally demonstrated that the introduction 
of mutations in the putative ORF of the lin-4 gene, did not 
affect its function, concluding that lin-4 did not encode for a 
protein. Mature lin-4 was found to be present in two small 
transcripts with different lengths, 22 and 61 nucleotides[24]. 
Furthermore, mutations in the 3’UTR of lin-14 mRNA 
and gene fusion experiments showed that lin-14 was 
downregulated posttranscriptionally by lin-4, delineating 
the 3’UTR of lin-14 as necessary for the regulation of LIN-4 
protein levels[25,26]. These data led to a unified conclusion: 
lin-4 transcripts were complementary to the 3’UTR of the 
lin-14 gene and regulated its expression by annealing to its 
3’UTR. With a similar approach, seven years later another 
miRNA was discovered, let-7, which was able to regulate 
lin-41 expression by binding to its 3’UTR[27,28]. Further, the 
sequence of let-7 was found conserved among species, 
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from flies to humans. A new era in transcriptomics was 
now open for study by the entire scientific world!
miRNA biogenesis and function
miRNA biogenesis occurs in two main steps that take 
place in the nucleus and in the cytoplasm. miRNA genes 
are transcribed by RNA polymerase Ⅱ and processed 
through both a canonical and a non-canonical biogenesis 
pathway. During canonical biogenesis primary miRNAs 
(pri-miRNAs) are processed into the nucleus by the RNase 
Ⅲ Drosha generating an approximately 70 nucleotide-
long precursor miRNA (pre-miRNA) product. In the non-
canonical pathway pre-miRNAs are instead generated 
by the mRNA splicing machinery, avoiding Drosha dig-
estion[29]. The subsequent steps are identical in both 
the canonical and non-canonical pathways. Pre-miRNAs 
are recognized by the Ran-GTP dependent transporter 
Exportin 5, which mediates their translocation to the 
cytoplasm. Here, Dicer, an other RNase type Ⅲ enzyme, 
cleaves the pre-miRNA hairpins and the mature miRNAs 
generated by this mechanism are loaded into miRISC 
(miRNA associated RNA induced silencing complex), where, 
with the help of Argonaute proteins, they act as post-
transcriptional regulators[30]. It is clear that, due to its 
complexity, the system of miRNA biogenesis requires 
a tight control. Transcriptional regulation remains the 
preferential process of miRNA expression control[31]. 
Knockout of Drosha causes the entire ablation of canonical 
miRNA production, suggesting its essential role in miRNA 
biogenesis[32]. DGCR8 is able to stabilize the Drosha 
complex by binding to Drosha itself. Drosha reduces 
DGCR8 expression[33,34]. It has also been shown that 
high levels of DGCR8 compromise Drosha activity[35]. 
Thus, complex networks may regulate Drosha complex 
activity. Dicer-deleted cells, instead, show some detectable 
canonical miRNAs, even if at reduced levels. What is more, 
Dicer is destabilized by low expression of TRBP. These 
data reveal the important, but not essential contribution of 
Dicer in the miRNA biogenesis pathway[32,36,37]. 
miRNA biogenesis is characterized by a physical 
separation between Drosha (nucleus) and Dicer (cyto-
plasm). Nervertheless, several mature miRNAs are 
located in the nucleus, like miR-29[38,39], or in the mitho-
condria, such as miR-1 and miR-181[40-42], or in small 
vesicles, suggesting non-canonical roles for miRNAs. 
Particularly, several studies reveal that miRNAs are 
transported into the nucleus, where they regulate the 
maturation of other miRNAs, by targeting their primary 
transcript, or control their own expression. Here, they can 
also bind long ncRNAs and thus regulate their expression 
and maturation[43]. In conclusion, it would be important 
for miRNA characterization to explore potential roles in 
non-canonical functions.
The function of miRNAs was first defined 20 years 
ago. A mature miRNA loaded into the RISC, is capable 
to bind and regulate the expression of target mRNA via 
base-pairing. In particular, miRNAs bind the 3’UTR of 
target mRNAs through a sequence of 2-8 nucleotides 
in their 5’end, termed seed region (Figure 1A). The 
partial or perfect complementarity between miRNAs and 
target mRNAs causes repression of translation or mRNA 
degradation, respectively[44] (Figure 1B). Owing to the 
short base pairing between a miRNA and the 3’UTR of 
its target mRNA, the interaction is dynamic: One miRNA 
can bind sequentially to hundreds of target mRNAs and 
a single mRNA can be targeted by several miRNAs[20]. 
miRNAs are able to select and interact with their targets 
based on Ⅰ) their expression levels or Ⅱ) expression 
levels of their mRNA targets. Since the expression and 
function of some miRNAs are species- and/or tissue-
specific, the co-localization of a miRNA with its mRNA 
target is clearly necessary for its functionality[45]. Moreover, 
tissue-specific miRNAs can localize both in intragenic and 
intergenic regions, and consequently they could be under 
the control of host gene promoters or, alternatively, they 
could hold their own promoter. Hence, for the intragenic 
miRNAs, expression could also be dependent on the 
transcription of host genes[46], suggesting the latter to be 
able to influence miRNA function. 
Summarizing, by selecting their targets in a dose-
dependent manner, miRNAs could control the balance of 
specific cellular processes.
Recent reports have suggested that in addition to the 
classical binding of miRNAs to the 3’UTR of mRNAs, they 
are able to bind also the 5’UTR region and ORF[47,48]. Sites 
located in coding regions and in 5’UTRs appear to be less 
robust than those in 3’UTR and, surprisingly, determine 
translational activation, and not repression, of miRNA-
targeted mRNAs. This situation has been described upon 
growth arrest conditions[49,50] (Figure 1C). However, these 
models are not universally accepted because ribosomes 
that scan the 5’UTR and the ORF are expected to remove 
annealed miRNAs.
Nowadays, the miRNA landscape is very tangled as 
the number of miRNA genes is exponentially growing[51], 
rendering it much more difficult to clearly define their 
function. miRNA genes have been clustered into diffe-
rent groups, known as miRNA families, based on the 
sequence of mature miRNAs or on the structure of pre-
miRNAs. This clusterization is really relevant for studying 
miRNA functions, since miRNA genes belonging to the 
same family co-localize and take place in the same 
specific mechanism, e.g., immune system regulation, 
development or cancer[52]. Moreover, the increasing 
number of novel miRNAs reveals that some of them are 
evolutionarily conserved whilst others are species- and/or 
tissues-specific. The expression levels of both the newly 
discovered and the long-known miRNAs are different 
from tissue to tissue, unraveling a differential tissue- and 
cell specific-functional impact of miRNAs[53]. 
miRNAs AND TRANSLATION 
REGULATION
mRNA translation is a cellular process finely regulated 
during growth and development, and its control is 
Oliveto S et al . miRNAs in translation regulation and cancer
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essential to maintain physiological processes in the cell. 
Translational control plays the major role in regulation 
of gene expression[54] and miRNAs take part in the 
regulation of mRNA translation.
Since a miRNA binds the 3’UTR of a target mRNA, 
how can it inhibit its translation? To date it is very clear that 
miRNAs contribute to the regulation of protein synthesis 
in two ways, mRNA destabilization or translational 
repression. Unfortunately, to date, a general mechanism 
for the translational inhibition by miRNAs has not been 
widely accepted; we rely on several different models that 
will be critically presented[55]. mRNA translation is divided 
in four phases: Initiation, elongation, termination and 
recycling. Here we will review in detail how miRNAs can 
repress translation at the initiation, post-initiation and 
elongation steps (Figure 2).
Initiation of translation
Initiation is the rate-limiting step in translation of a given 
mRNA and leads to the formation of the ribosome-tRNA-
mRNA complex. The golden method to analyze the step 
at which the translation of a specific mRNA is blocked is 
measuring the localization of the same mRNA in a sucrose 
polysome gradient. The general assumption is that a 
translated mRNA associates with multiple ribosomes 
(polysomes) and co-sediments to the heavy part of the 
gradient. Several in vitro studies reveal that repressed 
mRNAs shift to the lighter region of the sedimentation 
gradient, indicating reduced ribosome loading of the 
repressed mRNAs[56]. The mechanistic effect of miRNAs at 
initiation is confirmed by studies in which Ago was found 
bound to the translational machinery. Briefly, mammalian 
Ago2 is able to bind the m7G-cap of mRNA directly, 
suggesting that Ago2 and the cap binding protein eIF4E 
compete for association with the cap structure[57]. In this 
model miRNAs prevent translation of capped but not 
Internal Ribosome Entry Site (IRES) containing mRNAs. 
The discovery of a specific Ago2 domain responsible 
for the interaction with the cap structure supports the 
above hypothesis. Mutation of two key amino acids in 
Ago2 disrupts cap-Ago2 binding, and abolishes also the 
association between Ago2 and GW182, the latter being 
an important factor in miRNA mediated repression[58,59]. 
In vitro studies suggest other mechanisms of miRNA 
repression at the initiation step. For some studies, the 
presence of the m7G-cap is necessary for translational 
inhibition. Other studies demonstrated that miRNA-me-
diated repression impairs also cap-independent, IRES-
initiated translation, and exclude eIF4E-cap recognition 
as a target for miRNA function[60,61]. This consideration is 
complicated by kinetic issues, as IRES-containing mRNAs 
are in general less efficiently translated, but also by the 
fact that some mRNAs have both a m7G-cap and an 
IRES. 
5′UTR miRISC
ORF60S
40SeIF4E
5′CAP
AAAAA 
3’UTR
Translation inhibition mRNA degradation
5′UTR
60S
40S
ORF
miRISC
AAAAA 3'UTR
5′ UTR
60S
40S ORF
miRISC
AAAAA 3'UTR
Translation activation
5′UTR
60S
40S ORF
miRISC
AAAAA 3'UTR
5′ UTR
miRISC
60S
40S AAAAA 3'UTRORF
Quiescent cells Proliferative cells
A
B
C
Figure 1  Mechanisms of action of microRNAs. A: miRNAs bind the 3’UTR of a target gene by base pairing. The binding between the miRNA seed sequence 
(nucleotides 2-8 at the 5’end of the miRNA sequence) and the miRNA regulatory element (MRE) at the 3’UTR of a target gene determines the specific type of 
regulation; B: miRNAs act as inhibitors of translation when the binding at the 3’UTR of target genes is only partially complementary. Instead, when the binding 
complementarity is perfect, miRNAs induce mRNA degradation; C: miRNAs can also function in an unconventional manner: Under specific conditions, particularly 
during quiescence, they can activate translation by binding non canonical sites in the 5’UTR of target genes. ORF: Open reading frames.
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Studies performed on D. Melanogaster and mouse 
cells indicate that miRNAs impair the association of 
mRNAs to 40S or 80S ribosomes, probably disrupting the 
mRNA-40S complex[62]. In this study an excess of eIF4F 
ameliorates the miRNA mediated inhibition of a specific 
mRNA. Other in vitro studies confirmed that translational 
repression exists only in the presence of both the m7G 
cap and poly-A tail, indicating that polyadenylation itself 
may have a role in miRNA mediated repression[63-66]. 
Several hypotheses were proposed: (1) the CCR4-NOT 
deadenylation complex is sufficient to mediate silencing 
and could inhibit mRNA translation independently of 
its deadenylation activity[67,68]; (2) miRISC is able to 
inhibit 43S scanning by impairing eIF4F function[69,70], 
in particular NOT1 interaction with eIF4A2 could block 
eIF4A2 function and consequently 43S scanning; and 
(3) in contrast to hypothesis 2, a very recent study 
suggests that eIF4A activity and 43S ribosomal scanning 
are not required for miRNA silencing. In this context 
AGOs, GW182, CCR4-NOT and DDX6 complexes are 
able to repress and degrade mRNAs in a 43S scanning-
independent manner[65]. It is evident that conflicting 
reports may be due to difficulties in the analysis of the fast 
translation inhibition driven by miRNAs.
In addition, in the intertwined scenario of mRNA 
translational inhibition and mRNA degradation driven by 
miRNAs, the recurrent question is which step precedes 
the other. Recent studies performed in human cells, 
zebrafish, and D. Melanogaster, show that miRNAs reduce 
translation just before mRNA deadenylation and decay. 
Kinetic analysis monitoring in parallel the level of mRNAs, 
proteins and poly-A tail lengths coupled with ribosome 
profiling data, revealed that protein levels are affected 
prior to mRNA stability and poly-A tail lenght[63,64,71]. A 
recent work presents another interesting hypothesis: 
miRNAs destabilize mRNAs when they are in a ribosome 
free state, but at the same time mRNAs targeted by 
miRNAs are fully polysome associated. The authors 
demonstrate that while mRNAs are associated with 
polysomes, the decapping mechanism occurs proceeding 
in a 5’ to 3’ direction following the last translating ribo-
some[66]. According to this model miRNA mediated mRNA 
decay occurs cotranslationally, providing a solution to this 
complex mistery. 
Finally, it has been also suggested that miRNAs 
act at the level of active 80S complex formation, by 
affecting 60S joining. Eukaryotic Initiation Factor 6 
(eIF6) associates with the 60S ribosomal subunit and is 
able to coimmunoprecipitate with the Ago2-Dicer-TRBP 
complex. Studies in human cells and C. Elegans led to 
the conclusion that miRISC, when associated with eIF6, 
abolishes polysome formation, disrupting 80S ribosomes 
assembly[72]. However, these results were not confirmed 
in D. Melanogaster cells, where depletion of eIF6 had no 
effect in miRNA-mediated inhibition[73]. Furthermore all 
published data converge on the idea that eIF6 acts as an 
anti-association factor that, by binding the 60S ribosomal 
subunit, prevents the formation of active 80S[74,75]. 
This mechanism is regulated by post-translational mod-
ifications. Indeed eIF6 is activated downstream of the 
RACK1-PKCβⅡaxis[76,77] through phosphorylation on residue 
Ser235, an event which is found deregulated in several 
types of cancer[78-80].
Post-initiation and elongation of translation
At the end of the initiation step, the mRNA is positioned 
on the ribosome and amino acids are bound together 
to form a polypeptide chain, thus determining the inter-
mediate step of translation. Since 1999, by sedimen-
tation velocity ultracentrifugation in a sucrose gradient, 
it has been reported that some miRNAs fully associate 
with polysomes[81,82]. The copurification of miRNAs 
with polysomes, confirmed by many studies in the 
last years, not only proves that miRNAs are involved 
in translational repression, but suggests that miRNA 
targets are actively translated. Taken together, these data 
suggest that mRNAs could be silenced by miRNAs at 
the post initiation step. Some examples will clarify the 
situation. Most miRNAs are shown to be associated with 
polysomes and in particular let-7 is capable to cosediment 
with polyribosomes[82,83]. When translation is blocked, 
by either hypertonic stress or puromycin treatment, 
miRNAs are no longer associated with polysomes, 
differently from their mRNA targets. The latter in fact 
dissociate from polyribosomes only partially, suggesting 
a reduction of translational elongation or impairment 
of the post initiation step. The capability of miRNAs to 
repress translation could also depend on their strength 
in associating with polyribosomes, i.e., the amount of a 
specific miRNA in polysomes relative to its total quantity. 
Molotski and coworkers quantified the association of 
miRNAs with polysomes[83], and, in line with this study, we 
discovered that in a Mesothelioma cellular model, only 8% 
of the miRNAs analyzed is stable and enriched on polysomes 
(data not published), suggesting that the preference for a 
microRNA to bind polyribosomes might depend on: (1) the 
specific seed sequence of the microRNA; (2) the level of 
miRISC3’ 5’
miRNA
Repression of 
translation
Initiation Post-initiation Elongation 
Figure 2  Schematic representation of microRNAs role in translation. miRNAs 
can inhibit protein synthesis at three different stages of translation: Initiation, the 
rate limiting step, post initiation and elongation. For details refer to text.
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pairing energy between the miRNA and its target mRNA; 
and (3) the fact that target mRNAs are being translated 
or not. Overall what these data suggest is that the miRNA 
ability to repress translation could also depend on the 
rate of association with polysomes. However, how these 
small non-coding RNAs are capable to impair elongation 
or termination of translation is unclear. It has been also 
proposed that proteins synthesized from miRNA-targeted 
mRNAs are not able to accumulate because they are 
degraded by certain proteases employed by microRNA 
ribonucleoprotein complexes (miRNPs)[81], thus proposing 
another mechanism on how miRNAs might function.
miRNA “surprise” role: miRNA-dependent activation of 
translation
The dynamic interactions between miRNAs and mRNAs 
open new frontiers in the field of miRNome studies. 
Most miRNAs negatively regulate gene expression 
and led scientists to deeply characterize the binding 
mechanism of miRNAs seed sequence to mRNAs. It is 
clear that miRNAs bind 3’UTRs and repress translation 
of target mRNAs. The demonstration that miR-369 has 
the capacity to either activate or repress protein trans-
lation[84] raised the question on why and how miRNAs 
activate translation of their target mRNAs. When cells 
are grown in normal growth factor conditions, target 
mRNAs are translationally inhibited or decayed. Instead, 
in the absence of growth factors, i.e., in serum starved 
conditions, the same miRNAs are able to activate trans-
lation and increase the protein levels of their target 
mRNAs, as it happens with miR-369 and its target TNF 
alfa[84-86]. Nevertheless this is not true for all miRNAs. For 
example, when miR-16 targets TNF alfa in a different 3’
UTR region from that targeted by miR-369, it inhibits 
translation also in quiescent conditions[86,87]. This suggests 
that, when a cell exits the cell cycle, activation of translation 
depends on miRNAs seed sequences and on miRNA-mRNA 
base pairing. It has also been demonstrated that the 
repression or activation of translation requires the FXR1 
protein and Ago2, and that other miRNAs, among which 
let-7, respond to serum starvation upregulating trans-
lation of their target mRNAs[85,86]. 
New paradigms discovered more recently make the 
mechanism of miRNA regulation even more puzzling. 
In the recent years, non-canonical sites of binding have 
been reported. Such sites map to the 5’UTR and coding 
regions of mRNAs[88,89]. Several studies reported that 
miR-122 and miR-103a-3p have their target sites in 5’
UTR[90,91], and that some miRNAs are even able to target 
both 3’ and 5’UTRs. Moreover, under cellular stress miR-
10a activates translation by binding the 5’UTR of its 
target ribosomal protein coding mRNA[48]. All of these 
mechanisms, and probably several others yet unknown, 
render the landscape of miRNAs mode of action even 
more difficult to assess. In conclusion, it is essential to 
study the function of each miRNA singularly and in a 
specific cellular context in order to understand its precise 
function.
miRNAs AND CANCER
Cancer is a pathological condition in which gene ex-
pression is dramatically deregulated. miRNAs affect all 
steps of tumor progression including tumor growth, 
invasion, metastatic capability and angiogenesis. The 
relevance of miRNAs in cancer has been highlighted by 
alterations in their expression (Table 1) and consequently 
by the deregulation of the expression of their target 
mRNAs[92,93]. The first evidence of the involvement of 
miRNA in cancer derived from studies on chronic lym-
phocytic leukemia (CLL). Croce’s group discovered that 
two miRNAs, miR-15a and miR-16-1 derive from the same 
polycistronic RNA which is transcribed from a specific 
region of chromosome 13, frequently found deleted in 
CLL. Analyzing a set of CLL patients, they found that 
69% of them presented the deletion of miR-15-a and 
miR-16-1[44]. Moreover, they realized that a significant 
percentage of miRNA genes localizes in fragile sites and/
or in genome regions which often show chromosomal 
alterations, including amplifications or deletions. This 
last finding suggested that miRNAs are a new class of 
genes important in regulating cancer pathogenesis and 
development. These relevant and preliminary observations 
implemented the need for investigation with new advanced 
technologies. All known miRNAs are now mapped and the 
development of several new platforms is helpful to study 
the miRNome in both normal and pathological tissues and 
for the estabilishment of tumor classification, diagnosis 
and prognosis by miRNA profiling[94-96]. 
Just like classical protein-coding genes, also miRNA 
Cancer type
OncomiRs
   miR17-92[108] B-cell lymphoma, small cell lung cancer, 
colon cancer, gastric cancer
   miR-21[107] Breast, colon and lung cancer, glioblastoma
   miR-106[133] Gastric cancer, colorectal cancer
   miR-10b[113] Breast cancer
   miR-191[134,135] Human colorectal and breast cancer
Tumor suppressor miRNAs
   let-7[105,106] Lung cancer, Burkitt lymphoma
   miR-15a, miR16-1[103,104] CLL, prostate cancer, mesothelioma
   miR-29[136] Lung cancer, breast cancer
   miR-34a[116] Prostate cancer, mesothelioma, HCC
   miR-126[114] Lung and breast cancer
Both O and TS
   miR-24[137,138] Breast cancer, glioma (O) 
Laryngeal carcinoma (TS)
   miR-125[122,123] Pancreatic and prostate cancer (O) 
Melanoma, osteosarcoma, ovarian 
cancer (TS)
   miR-155[120,121] Lymphoma, breast cancer (O) 
Melanoma, ovarian and gastric cancer (TS)
   miR-221/222[139] Glioblastoma, HCC, breast cancer (O) 
Tongue squamous cell carcinoma (TS)
Table 1  List of selected tumor suppressor microRNAs and 
oncomiRs in cancer
CLL: Chronic lymphocytic leukemia; HCC: Hepatocellular carcinoma; O: 
OncomiR; TS: Tumor suppressor miRNA.
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genes can be altered by promoter methylation, chro-
mosomal amplifications, deletions and transcriptional 
activation. Genetic alterations may involve the miRNA 
machinery[97] or alter the target binding site[98], the 
processing of miRNAs and their post-transcriptional 
editing[99]. In cancer, dysregulated miRNAs can act as 
oncogenic miRNAs (oncomiRs) or tumor suppressor 
miRNAs, based on their capability to repress the ex-
pression of tumor suppressor genes or oncogenes, 
respectively (Figure 3). The inhibition or stimulation 
of oncomiRs or tumor suppressor miRNAs modulates 
cancer cell proliferation, tumor growth, metastasis 
formation and cell survival[100]. Generally, oncomiRs, which 
modulate tumor suppressor proteins, are overexpressed 
in cancer, whilst tumor suppressor miRNAs, which target 
oncoproteins, are downregulated or deleted. Tumor 
suppressors miR-15a and miR-16-1, whose target is 
Bcl-2[101,102], are downregulated in several cancers, such 
as mesothelioma[103], CLL and prostate carcinoma[104], 
tumor suppressor let-7 targets RAS and Myc[105,106], while 
oncomiR miR-21 is overexpressed in breast cancer, colon 
cancer and glioblastoma and targets PTEN in non-small 
cell lung cancer[107]. Furthermore, the most studied miRNA 
cluster, miR17-92 is able to induce lymphomagenesis in 
a B-cell specific transgenic mice[108], and miR-19, miR-
20a and miR-92, which are part of this cluster, promote 
T cell ALL development in mouse models[109]. It has been 
established that knocking down the upregulated oncomiRs 
reduces cell proliferation and tumor growth both in vitro 
and in vivo tumor systems[110-112]. In addition to classical 
tumor suppressor or oncogene functions, miRNAs are also 
involved in cell migration and metastasis formation. In 
breast cancer miR-10b modulation increases cell invasion 
and migration by targeting HOXD10 and eliciting the 
expression of the pro-metastatic gene RHOC[113]. Other 
examples are miR-335 and miR-126, which act as nega-
tive regulators of metastasis and tumor invasion in lung 
and breast cancer[114,115]. miR-34a, instead, is lost in 
several tumors and is involved in the p53 pathway[116]. 
Moreover, miR-34a is able to inhibit migration and invasion 
downregulating MET expression in HCC cells[117]. 
Several miRNAs cannot be clearly and unequivocally 
categorized as tumor suppressors or oncomiRs given that 
the data in our hands are quite intricate and conflicting 
since they could act as tumor suppressors in one scenario 
or as oncomiRs in the other (Table 1). This is not surprising 
considering that the same miRNA may regulate from ten 
to hundreds of genes involved in completely different 
cellular pathways. If we consider miR-155, it works as 
an oncomiR in solid and hematological malignancies, 
such as lymphoma and breast cancer[118,119], but in 
melanoma, as well as in ovarian and gastric cancer, it 
shows a tumor suppressor role[120,121]. Another relevant 
example is represented by miR-125, which shows tumor 
suppressor properties in several cancers, like mela-
noma, osteosarcoma, ovarian and breast cancer, and 
tumor promoting functions in pancreatic and prostate 
cancers[122,123]. It is clear that the dual role of miRNAs 
could be due to the heterogeneity and variability of cancer, 
causing the same miRNA to carry out different effects in 
different tumors. 
miRNAs have also an important role in the clinic 
where they are useful in terms of diagnosis, prognosis 
and prediction of therapy response. In this context 
miRNAs expression can be used as a tool to predict 
tumorigenesis and overall survival, but also to classify 
malignant and non-malignant tissues. To date, the clinical 
importance of miRNAs has been demonstrated for several 
types of cancers and by using also biopsies or surgery 
specimens[124]. 
To avoid the invasiveness of surgery techniques, se-
veral studies focused their attention on analyzing miRNA 
expression levels in human fluids, such as plasma/serum, 
saliva and urine, speculating the idea that circulating 
OncomiR
   miR-21
   miR-10b
   miR-191
miRNA
Tumor suppressor gene 
Normal cell
Tumorigenesis
Malignant tumor
miRNA
Oncogene
Tumor suppressor miRNA
   miR-15a
   miR16-1
   miR-34a
Figure 3  Roles of microRNAs in cancer. miRNAs suppress the expression of their target genes. An oncogenic miRNA, termed oncomiR, can repress the translation 
of a tumor suppressor gene, stimulating tumorigenesis and leading to tumor formation. Conversely, a tumor suppressor miRNA is able to inhibit the expression of 
oncogenes, blocking the tumorigenesis process and consequently the development of cancer.
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miRNAs could be stable and therefore useful clinical 
biomarkers. To support this idea, to date, miRNA deregu-
lation in serum of cancer patients has been described for 
several types of tumors such as leukemia, lymphoma, 
gastric, lung, ovarian, prostate, pancreatic and breast 
cancer[125]. Most miRNAs found outside of cells, particularly 
in body fluids, are stable, and this is quite surprising since 
most RNA molecules in the extracellular environment are 
subjected to ribonucleases. These observations suggest 
that secreted miRNAs could be protected by degrada-
tion possibly by being packed in particular extracellular 
vesicles[126]. 
Among extracellular vesicles, exosomes turn out to 
be the most studied membrane bound vesicles released 
from cells into the extracellular space[127]. Exosomes play 
an important role in exchanging information between 
cancer cells, and such cell-to-cell communication is essential 
for tumor survival and progression and for metastases 
formation. Several studies identified exosomes as the 
key components of this process, and the idea that ex-
tracellular miRNA are among the mediators used by 
exosomes for this inter-cell communication makes this 
model even more attractive. In line with these data, 
several studies showed that exosomal miRNA expression 
is altered in cancer[128,129]. The function of exosomal 
miRNAs is poorly understood, but some reports showed 
that in this context they carry out their conventional role 
of negative regulators of gene expression. One example 
is miR-105 which, once released from breast cancer 
cell lines, reduces ZO-1 gene expression and promotes 
metastases formation in the lung and brain[130]. Recently, 
a novel and peculiar function of exosomal miR-21 and 
miR-29a was demonstrated: Such miRNAs are capable 
to activate immune cells, by acting as toll-like receptors 
ligands[131]. 
These observations and future progresses in the 
miRNA research field will be very helpful for the de-
velopment of new therapeutical strategies to fight 
cancer. Indeed, when a cancer is characterized by the 
overexpression of specific miRNAs, the use of anti-
miRs as drugs could help restoring the non-pathological 
condition. On the contrary, the same results could be 
obtained by the use of miRNA mimics in cancers in which 
specific miRNAs are downregulated. A similar approach 
was described by Kota et al[132]: The restoring of miR-26a 
in hepatocellular carcinoma is able to reduce cancer cell 
proliferation by triggering apoptosis. These data widely 
show that miRNAs have a precious potential to act as 
therapeutical targets.
CONCLUSION
In conclusions, the miRNA world is fascinating and 
mysterious. The number of miRNA genes that are being 
discovered is increasing and novel mechanisms of action 
might reveal possible new therapeutic strategies. The fact 
that miRNAs use non-canonical target sites to perform 
their function opens a puzzling scenario that could lead 
researchers to discover completely new miRNA functions 
and modes of action. Although great strides have been 
made in the recent years, the comprehension of the 
global miRNome and the establishment of functional 
therapeutic strategies in miRNA cancer research are yet 
far from being achieved. The discovery and development 
of miRNA inhibitors or miRNA mimics as novel drugs will 
offer new hopes in the fight against cancer.
REFERENCES
1 Alexander RP, Fang G, Rozowsky J, Snyder M, Gerstein MB. 
Annotating non-coding regions of the genome. Nat Rev Genet 
2010; 11: 559-571 [PMID: 20628352 DOI: 10.1038/nrg2814]
2 Spadafora C. A LINE-1-encoded reverse transcriptase-depen-
dent regulatory mechanism is active in embryogenesis and 
tumorigenesis. Ann N Y Acad Sci 2015; 1341: 164-171 [PMID: 
25586649 DOI: 10.1111/nyas.12637]
3 Elbarbary RA, Lucas BA, Maquat LE. Retrotransposons as 
regulators of gene expression. Science 2016; 351: aac7247 [PMID: 
26912865 DOI: 10.1126/science.aac7247]
4 Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: 
insights into functions. Nat Rev Genet 2009; 10: 155-159 [PMID: 
19188922 DOI: 10.1038/nrg2521]
5 Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 
2011; 12: 861-874 [PMID: 22094949 DOI: 10.1038/nrg3074]
6 Mihailescu R. Gene expression regulation: lessons from 
noncoding RNAs. RNA 2015; 21: 695-696 [PMID: 25780195 DOI: 
10.1261/rna.050815.115]
7 Croce CM. Causes and consequences of microRNA dysregulation 
in cancer. Nat Rev Genet 2009; 10: 704-714 [PMID: 19763153 
DOI: 10.1038/nrg2634]
8 Mendell JT. MicroRNAs: critical regulators of development, 
cellular physiology and malignancy. Cell Cycle 2005; 4: 1179-1184 
[PMID: 16096373 DOI: 10.4161/cc.4.9.2032]
9 Watanabe T, Tomizawa S, Mitsuya K, Totoki Y, Yamamoto Y, 
Kuramochi-Miyagawa S, Iida N, Hoki Y, Murphy PJ, Toyoda 
A, Gotoh K, Hiura H, Arima T, Fujiyama A, Sado T, Shibata T, 
Nakano T, Lin H, Ichiyanagi K, Soloway PD, Sasaki H. Role for 
piRNAs and noncoding RNA in de novo DNA methylation of 
the imprinted mouse Rasgrf1 locus. Science 2011; 332: 848-852 
[PMID: 21566194 DOI: 10.1126/science.1203919]
10 Brennecke J, Aravin AA, Stark A, Dus M, Kellis M, Sachida-
nandam R, Hannon GJ. Discrete small RNA-generating loci 
as master regulators of transposon activity in Drosophila. Cell 
2007; 128: 1089-1103 [PMID: 17346786 DOI: 10.1016/j.cell. 
2007.01.043]
11 Kuramochi-Miyagawa S, Watanabe T, Gotoh K, Takamatsu 
K, Chuma S, Kojima-Kita K, Shiromoto Y, Asada N, Toyoda A, 
Fujiyama A, Totoki Y, Shibata T, Kimura T, Nakatsuji N, Noce 
T, Sasaki H, Nakano T. MVH in piRNA processing and gene 
silencing of retrotransposons. Genes Dev 2010; 24: 887-892 [PMID: 
20439430 DOI: 10.1101/gad.1902110]
12 Deschamps-Francoeur G, Garneau D, Dupuis-Sandoval F, Roy A, 
Frappier M, Catala M, Couture S, Barbe-Marcoux M, Abou-Elela S, 
Scott MS. Identification of discrete classes of small nucleolar RNA 
featuring different ends and RNA binding protein dependency. 
Nucleic Acids Res 2014; 42: 10073-10085 [PMID: 25074380 DOI: 
10.1093/nar/gku664]
13 Taft RJ, Kaplan CD, Simons C, Mattick JS. Evolution, biogenesis 
and function of promoter-associated RNAs. Cell Cycle 2009; 8: 
2332-2338 [PMID: 19597344 DOI: 10.4161/cc.8.15.9154]
14 Geisler S, Coller J. RNA in unexpected places: long non-coding 
RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 
2013; 14: 699-712 [PMID: 24105322 DOI: 10.1038/nrm3679]
15 Morceau F, Chateauvieux S, Gaigneaux A, Dicato M, Diederich M. 
Long and short non-coding RNAs as regulators of hematopoietic 
differentiation. Int J Mol Sci 2013; 14: 14744-14770 [PMID: 
23860209 DOI: 10.3390/ijms140714744]
Oliveto S et al . miRNAs in translation regulation and cancer
53 February 26, 2017|Volume 8|Issue 1|WJBC|www.wjgnet.com
16 Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, 
Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi 
S, Taccioli C, Pichiorri F, Liu X, Zupo S, Herlea V, Gramantieri L, 
Lanza G, Alder H, Rassenti L, Volinia S, Schmittgen TD, Kipps TJ, 
Negrini M, Croce CM. Ultraconserved regions encoding ncRNAs 
are altered in human leukemias and carcinomas. Cancer Cell 2007; 
12: 215-229 [PMID: 17785203 DOI: 10.1016/j.ccr.2007.07.027]
17 Scaruffi P, Stigliani S, Moretti S, Coco S, De Vecchi C, Valdora F, 
Garaventa A, Bonassi S, Tonini GP. Transcribed-Ultra Conserved 
Region expression is associated with outcome in high-risk neuro-
blastoma. BMC Cancer 2009; 9: 441 [PMID: 20003513 DOI: 
10.1186/1471-2407-9-441]
18 Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of 
ceRNA crosstalk and competition. Nature 2014; 505: 344-352 
[PMID: 24429633 DOI: 10.1038/nature12986]
19 de Klerk E, ‘t Hoen PA. Alternative mRNA transcription, pro-
cessing, and translation: insights from RNA sequencing. Trends 
Genet 2015; 31: 128-139 [PMID: 25648499 DOI: 10.1016/j.tig. 
2015.01.001]
20 Bartel DP. MicroRNAs: target recognition and regulatory 
functions. Cell 2009; 136: 215-233 [PMID: 19167326 DOI: 10.1016/
j.cell.2009.01.002]
21 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, 
and function. Cell 2004; 116: 281-297 [PMID: 14744438 DOI: 
10.1016/S0092-8674(04)00045-5]
22 Horvitz HR, Sulston JE. Isolation and genetic characterization 
of cell-lineage mutants of the nematode Caenorhabditis elegans. 
Genetics 1980; 96: 435-454 [PMID: 7262539]
23 Lee R, Feinbaum R, Ambros V. A short history of a short RNA. 
Cell 2004; 116: S89-S92, 1 p following S96 [PMID: 15055592]
24 Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic 
gene lin-4 encodes small RNAs with antisense complementarity to 
lin-14. Cell 1993; 75: 843-854 [PMID: 8252621]
25 Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of 
the heterochronic gene lin-14 by lin-4 mediates temporal pattern 
formation in C. elegans. Cell 1993; 75: 855-862 [PMID: 8252622]
26 Wightman B, Bürglin TR, Gatto J, Arasu P, Ruvkun G. Negative 
regulatory sequences in the lin-14 3’-untranslated region are necessary 
to generate a temporal switch during Caenorhabditis elegans 
development. Genes Dev 1991; 5: 1813-1824 [PMID: 1916264]
27 Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, 
Rougvie AE, Horvitz HR, Ruvkun G. The 21-nucleotide let-7 RNA 
regulates developmental timing in Caenorhabditis elegans. Nature 
2000; 403: 901-906 [PMID: 10706289 DOI: 10.1038/35002607]
28 Vella MC, Choi EY, Lin SY, Reinert K, Slack FJ. The C. elegans 
microRNA let-7 binds to imperfect let-7 complementary sites from 
the lin-41 3’UTR. Genes Dev 2004; 18: 132-137 [PMID: 14729570 
DOI: 10.1101/gad.1165404]
29 Li Z, Rana TM. Therapeutic targeting of microRNAs: current 
status and future challenges. Nat Rev Drug Discov 2014; 13: 
622-638 [PMID: 25011539 DOI: 10.1038/nrd4359]
30 Li Z, Rana TM. Molecular mechanisms of RNA-triggered gene 
silencing machineries. Acc Chem Res 2012; 45: 1122-1131 [PMID: 
22304792 DOI: 10.1021/ar200253u]
31 Krol J, Loedige I, Filipowicz W. The widespread regulation of 
microRNA biogenesis, function and decay. Nat Rev Genet 2010; 
11: 597-610 [PMID: 20661255 DOI: 10.1038/nrg2843]
32 Kim YK, Kim B, Kim VN. Re-evaluation of the roles of 
DROSHA, Export in 5, and DICER in microRNA biogenesis. Proc 
Natl Acad Sci USA 2016; 113: E1881-E1889 [PMID: 26976605 
DOI: 10.1073/pnas.1602532113]
33 Han J, Pedersen JS, Kwon SC, Belair CD, Kim YK, Yeom KH, 
Yang WY, Haussler D, Blelloch R, Kim VN. Posttranscriptional 
crossregulation between Drosha and DGCR8. Cell 2009; 136: 
75-84 [PMID: 19135890 DOI: 10.1016/j.cell.2008.10.053]
34 Triboulet R, Chang HM, Lapierre RJ, Gregory RI. Post-
transcriptional control of DGCR8 expression by the Microprocessor. 
RNA 2009; 15: 1005-1011 [PMID: 19383765 DOI: 10.1261/
rna.1591709]
35 Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, 
Cooch N, Shiekhattar R. The Microprocessor complex mediates 
the genesis of microRNAs. Nature 2004; 432: 235-240 [PMID: 
15531877 DOI: 10.1038/nature03120]
36 Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, 
Calin GA, Rossi S, Fernandez AF, Carneiro F, Oliveira C, Ferreira 
B, Liu CG, Villanueva A, Capella G, Schwartz S, Shiekhattar 
R, Esteller M. A TARBP2 mutation in human cancer impairs 
microRNA processing and DICER1 function. Nat Genet 2009; 41: 
365-370 [PMID: 19219043 DOI: 10.1038/ng.317]
37 Paroo Z, Ye X, Chen S, Liu Q. Phosphorylation of the human 
microRNA-generating complex mediates MAPK/Erk signaling. 
Cell 2009; 139: 112-122 [PMID: 19804757 DOI: 10.1016/
j.cell.2009.06.044]
38 Hwang HW, Wentzel EA, Mendell JT. A hexanucleotide element 
directs microRNA nuclear import. Science 2007; 315: 97-100 
[PMID: 17204650 DOI: 10.1126/science.1136235]
39 Roberts TC. The MicroRNA Biology of the Mammalian Nucleus. 
Mol Ther Nucleic Acids 2014; 3: e188 [PMID: 25137140 DOI: 
10.1038/mtna.2014.40]
40 Zhang J, Li S, Li L, Li M, Guo C, Yao J, Mi S. Exosome and exo-
somal microRNA: trafficking, sorting, and function. Genomics 
Proteomics Bioinformatics 2015; 13: 17-24 [PMID: 25724326 DOI: 
10.1016/j.gpb.2015.02.001]
41 Zhang X, Zuo X, Yang B, Li Z, Xue Y, Zhou Y, Huang J, Zhao X, 
Zhou J, Yan Y, Zhang H, Guo P, Sun H, Guo L, Zhang Y, Fu XD. 
MicroRNA directly enhances mitochondrial translation during 
muscle differentiation. Cell 2014; 158: 607-619 [PMID: 25083871 
DOI: 10.1016/j.cell.2014.05.047]
42 Das S, Bedja D, Campbell N, Dunkerly B, Chenna V, Maitra A, 
Steenbergen C. miR-181c regulates the mitochondrial genome, 
bioenergetics, and propensity for heart failure in vivo. PLoS 
One 2014; 9: e96820 [PMID: 24810628 DOI: 10.1371/journal.
pone.0096820]
43 Chen X, Liang H, Zhang CY, Zen K. miRNA regulates noncoding 
RNA: a noncanonical function model. Trends Biochem Sci 2012; 
37: 457-459 [PMID: 22963870 DOI: 10.1016/j.tibs.2012.08.005]
44 Iorio MV, Croce CM. Causes and consequences of microRNA 
dysregulation. Cancer J 2012; 18: 215-222 [PMID: 22647357 
DOI: 10.1097/PPO.0b013e318250c001]
45 Shu J, Xia Z, Li L, Liang ET, Slipek N, Shen D, Foo J, Subra-
manian S, Steer CJ. Dose-dependent differential mRNA target 
selection and regulation by let-7a-7f and miR-17-92 cluster 
microRNAs. RNA Biol 2012; 9: 1275-1287 [PMID: 22995834 DOI: 
10.4161/rna.21998]
46 Lutter D, Marr C, Krumsiek J, Lang EW, Theis FJ. Intronic 
microRNAs support their host genes by mediating synergistic and 
antagonistic regulatory effects. BMC Genomics 2010; 11: 224 
[PMID: 20370903 DOI: 10.1186/1471-2164-11-224]
47 Moretti F, Thermann R, Hentze MW. Mechanism of translational 
regulation by miR-2 from sites in the 5’ untranslated region or the 
open reading frame. RNA 2010; 16: 2493-2502 [PMID: 20966199 
DOI: 10.1261/rna.2384610]
48 Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5’
UTR of ribosomal protein mRNAs and enhances their translation. 
Mol Cell 2008; 30: 460-471 [PMID: 18498749 DOI: 10.1016/
j.molcel.2008.05.001]
49 Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA 
translation and stability by microRNAs. Annu Rev Biochem 2010; 
79: 351-379 [PMID: 20533884 DOI: 10.1146/annurev-biochem- 
060308-103103]
50 Vasudevan S, Tong Y, Steitz JA. Cell-cycle control of microRNA-
mediated translation regulation. Cell Cycle 2008; 7: 1545-1549 
[PMID: 18469529 DOI: 10.4161/cc.7.11.6018]
51 Kamanu TK, Radovanovic A, Archer JA, Bajic VB. Exploration 
of miRNA families for hypotheses generation. Sci Rep 2013; 3: 
2940 [PMID: 24126940 DOI: 10.1038/srep02940]
52 Mathelier A, Carbone A. Large scale chromosomal mapping of 
human microRNA structural clusters. Nucleic Acids Res 2013; 41: 
4392-4408 [PMID: 23444140 DOI: 10.1093/nar/gkt112]
53 Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, 
Oliveto S et al . miRNAs in translation regulation and cancer
54 February 26, 2017|Volume 8|Issue 1|WJBC|www.wjgnet.com
Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, 
Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz 
LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, 
Yeh JJ, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van 
Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto 
J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos I. 
Analysis of 13 cell types reveals evidence for the expression of 
numerous novel primate- and tissue-specific microRNAs. Proc 
Natl Acad Sci USA 2015; 112: E1106-E1115 [PMID: 25713380 
DOI: 10.1073/pnas.1420955112]
54 Gebauer F, Hentze MW. Molecular mechanisms of translational 
control. Nat Rev Mol Cell Biol 2004; 5: 827-835 [PMID: 15459663 
DOI: 10.1038/nrm1488]
55 Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of 
post-transcriptional regulation by microRNAs: are the answers in 
sight? Nat Rev Genet 2008; 9: 102-114 [PMID: 18197166 DOI: 
10.1038/nrg2290]
56 Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, 
Basyuk E, Bertrand E, Filipowicz W. Inhibition of translational 
initiation by Let-7 MicroRNA in human cells. Science 2005; 309: 
1573-1576 [PMID: 16081698 DOI: 10.1126/science.1115079]
57 Kiriakidou M, Tan GS, Lamprinaki S, De Planell-Saguer M, 
Nelson PT, Mourelatos Z. An mRNA m7G cap binding-like 
motif within human Ago2 represses translation. Cell 2007; 129: 
1141-1151 [PMID: 17524464 DOI: 10.1016/j.cell.2007.05.016]
58 Kinch LN, Grishin NV. The human Ago2 MC region does not 
contain an eIF4E-like mRNA cap binding motif. Biol Direct 2009; 
4: 2 [PMID: 19159466 DOI: 10.1186/1745-6150-4-2]
59 Su H, Trombly MI, Chen J, Wang X. Essential and overlapping 
functions for mammalian Argonautes in microRNA silencing. 
Genes Dev 2009; 23: 304-317 [PMID: 19174539 DOI: 10.1101/
gad.1749809]
60 Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs 
repress translation after initiation in mammalian cells. Mol Cell 
2006; 21: 533-542 [PMID: 16483934 DOI: 10.1016/j.molcel. 
2006.01.031]
61 Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as 
efficiently by microRNA-binding sites in the 5’ UTR as in the 
3’ UTR. Proc Natl Acad Sci USA 2007; 104: 9667-9672 [PMID: 
17535905 DOI: 10.1073/pnas.0703820104]
62 Mathonnet G, Fabian MR, Svitkin YV, Parsyan A, Huck L, 
Murata T, Biffo S, Merrick WC, Darzynkiewicz E, Pillai RS, 
Filipowicz W, Duchaine TF, Sonenberg N. MicroRNA inhibition of 
translation initiation in vitro by targeting the cap-binding complex 
eIF4F. Science 2007; 317: 1764-1767 [PMID: 17656684 DOI: 
10.1126/science.1146067]
63 Bazzini AA, Lee MT, Giraldez AJ. Ribosome profiling shows 
that miR-430 reduces translation before causing mRNA decay in 
zebrafish. Science 2012; 336: 233-237 [PMID: 22422859 DOI: 
10.1126/science.1215704]
64 Djuranovic S, Nahvi A, Green R. miRNA-mediated gene silencing 
by translational repression followed by mRNA deadenylation 
and decay. Science 2012; 336: 237-240 [PMID: 22499947 DOI: 
10.1126/science.1215691]
65 Kuzuoğlu-Öztürk D, Bhandari D, Huntzinger E, Fauser M, 
Helms S, Izaurralde E. miRISC and the CCR4-NOT complex 
silence mRNA targets independently of 43S ribosomal scanning. 
EMBO J 2016; 35: 1186-1203 [PMID: 27009120 DOI: 10.15252/
embj.201592901]
66 Tat TT , Maroney PA, Chamnongpol S, Coller J, Nilsen 
TW. Cotranslational microRNA mediated messenger RNA 
destabilization. Elife 2016; 5: pii: e12880 [PMID: 27058298 DOI: 
10.7554/eLife.12880]
67 Bawankar P, Loh B, Wohlbold L, Schmidt S, Izaurralde E. NOT10 
and C2orf29/NOT11 form a conserved module of the CCR4-NOT 
complex that docks onto the NOT1 N-terminal domain. RNA Biol 
2013; 10: 228-244 [PMID: 23303381 DOI: 10.4161/rna.23018]
68 Zekri L, Kuzuoğlu-Öztürk D, Izaurralde E. GW182 proteins cause 
PABP dissociation from silenced miRNA targets in the absence of 
deadenylation. EMBO J 2013; 32: 1052-1065 [PMID: 23463101 
DOI: 10.1038/emboj.2013.44]
69 Fukao A, Mishima Y, Takizawa N, Oka S, Imataka H, Pelletier 
J, Sonenberg N, Thoma C, Fujiwara T. MicroRNAs trigger 
dissociation of eIF4AI and eIF4AII from target mRNAs in humans. 
Mol Cell 2014; 56: 79-89 [PMID: 25280105 DOI: 10.1016/
j.molcel.2014.09.005]
70 Ricci EP, Limousin T, Soto-Rifo R, Rubilar PS, Decimo D, 
Ohlmann T. miRNA repression of translation in vitro takes place 
during 43S ribosomal scanning. Nucleic Acids Res 2013; 41: 
586-598 [PMID: 23161679 DOI: 10.1093/nar/gks1076]
71 Béthune J, Artus-Revel CG, Filipowicz W. Kinetic analysis 
reveals successive steps leading to miRNA-mediated silencing in 
mammalian cells. EMBO Rep 2012; 13: 716-723 [PMID: 22677978 
DOI: 10.1038/embor.2012.82]
72 Chendrimada TP, Finn KJ, Ji X, Baillat D, Gregory RI, Liebhaber 
SA, Pasquinelli AE, Shiekhattar R. MicroRNA silencing through 
RISC recruitment of eIF6. Nature 2007; 447: 823-828 [PMID: 
17507929 DOI: 10.1038/nature05841]
73 Eulalio A, Huntzinger E, Izaurralde E. GW182 interaction 
with Argonaute is essential for miRNA-mediated translational 
repression and mRNA decay. Nat Struct Mol Biol 2008; 15: 
346-353 [PMID: 18345015 DOI: 10.1038/nsmb.1405]
74 Brina D, Miluzio A, Ricciardi S, Biffo S. eIF6 anti-association 
activity is required for ribosome biogenesis, translational control 
and tumor progression. Biochim Biophys Acta 2015; 1849: 830-835 
[PMID: 25252159 DOI: 10.1016/j.bbagrm.2014.09.010]
75 Sanvito F, Piatti S, Villa A, Bossi M, Lucchini G, Marchisio 
PC, Biffo S. The beta4 integrin interactor p27(BBP/eIF6) is an 
essential nuclear matrix protein involved in 60S ribosomal subunit 
assembly. J Cell Biol 1999; 144: 823-837 [PMID: 10085284 DOI: 
10.1083/jcb.144.5.823]
76 Gallo S, Manfrini N. Working hard at the nexus between cell 
signaling and the ribosomal machinery: An insight into the roles of 
RACK1 in translational regulation. Translation (Austin) 2015; 3: 
e1120382 [PMID: 26824030 DOI: 10.1080/21690731.2015.1120382]
77 Ceci M, Gaviraghi C, Gorrini C, Sala LA, Offenhäuser N, 
Marchisio PC, Biffo S. Release of eIF6 (p27BBP) from the 60S 
subunit allows 80S ribosome assembly. Nature 2003; 426: 579-584 
[PMID: 14654845 DOI: 10.1038/nature02160]
78 Miluzio A, Beugnet A, Grosso S, Brina D, Mancino M, Campaner 
S, Amati B, de Marco A, Biffo S. Impairment of cytoplasmic eIF6 
activity restricts lymphomagenesis and tumor progression without 
affecting normal growth. Cancer Cell 2011; 19: 765-775 [PMID: 
21665150 DOI: 10.1016/j.ccr.2011.04.018]
79 Miluzio A, Beugnet A, Volta V, Biffo S. Eukaryotic initiation 
factor 6 mediates a continuum between 60S ribosome biogenesis 
and translation. EMBO Rep 2009; 10: 459-465 [PMID: 19373251 
DOI: 10.1038/embor.2009.70]
80 Miluzio A, Oliveto S, Pesce E, Mutti L, Murer B, Grosso S, 
Ricciardi S, Brina D, Biffo S. Expression and activity of eIF6 trigger 
malignant pleural mesothelioma growth in vivo. Oncotarget 2015; 6: 
37471-37485 [PMID: 26462016 DOI: 10.18632/oncotarget.5462]
81 Olsen PH, Ambros V. The lin-4 regulatory RNA controls 
developmental timing in Caenorhabditis elegans by blocking 
LIN-14 protein synthesis after the initiation of translation. Dev 
Biol 1999; 216: 671-680 [PMID: 10642801 DOI: 10.1006/dbio. 
1999.9523]
82 Maroney PA, Yu Y, Fisher J, Nilsen TW. Evidence that microRNAs 
are associated with translating messenger RNAs in human cells. 
Nat Struct Mol Biol 2006; 13: 1102-1107 [PMID: 17128271 DOI: 
10.1038/nsmb1174]
83 Molotski N, Soen Y. Differential association of microRNAs with 
polysomes reflects distinct strengths of interactions with their 
mRNA targets. RNA 2012; 18: 1612-1623 [PMID: 22836355 DOI: 
10.1261/rna.033142.112]
84 Buchan JR, Parker R. Molecular biology. The two faces of 
miRNA. Science 2007; 318: 1877-1878 [PMID: 18096794 DOI: 
10.1126/science.1152623]
85 Vasudevan S, Tong Y, Steitz JA. Switching from repression to 
activation: microRNAs can up-regulate translation. Science 2007; 
Oliveto S et al . miRNAs in translation regulation and cancer
55 February 26, 2017|Volume 8|Issue 1|WJBC|www.wjgnet.com
318: 1931-1934 [PMID: 18048652 DOI: 10.1126/science.1149460]
86 Truesdell SS, Mortensen RD, Seo M, Schroeder JC, Lee JH, 
LeTonqueze O, Vasudevan S. MicroRNA-mediated mRNA trans-
lation activation in quiescent cells and oocytes involves recruitment 
of a nuclear microRNP. Sci Rep 2012; 2: 842 [PMID: 23150790 DOI: 
10.1038/srep00842]
87 Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di 
Padova F, Lin SC, Gram H, Han J. Involvement of microRNA 
in AU-rich element-mediated mRNA instability. Cell 2005; 120: 
623-634 [PMID: 15766526 DOI: 10.1016/j.cell.2004.12.038]
88 Brümmer A, Hausser J. MicroRNA binding sites in the coding 
region of mRNAs: extending the repertoire of post-transcriptional 
gene regulation. Bioessays 2014; 36: 617-626 [PMID: 24737341 
DOI: 10.1002/bies.201300104]
89 Cipolla GA. A non-canonical landscape of the microRNA system. 
Front Genet 2014; 5: 337 [PMID: 25295056 DOI: 10.3389/
fgene.2014.00337]
90 Roberts AP, Lewis AP, Jopling CL. miR-122 activates hepatitis C 
virus translation by a specialized mechanism requiring particular 
RNA components. Nucleic Acids Res 2011; 39: 7716-7729 [PMID: 
21653556 DOI: 10.1093/nar/gkr426]
91 Zhou H, Rigoutsos I. MiR-103a-3p targets the 5’ UTR of GPRC5A 
in pancreatic cells. RNA 2014; 20: 1431-1439 [PMID: 24984703 
DOI: 10.1261/rna.045757.114]
92 Choudhury M, Friedman JE. Epigenetics and microRNAs in 
preeclampsia. Clin Exp Hypertens 2012; 34: 334-341 [PMID: 
22468840 DOI: 10.3109/10641963.2011.649931]
93 Stahlhut C, Slack FJ. MicroRNAs and the cancer phenotype: 
profiling, signatures and clinical implications. Genome Med 2013; 
5: 111 [PMID: 24373327 DOI: 10.1186/gm516]
94 Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, 
Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, 
Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce 
CM. A microRNA expression signature of human solid tumors 
defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 
2257-2261 [PMID: 16461460 DOI: 10.1073/pnas.0510565103]
95 Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, 
Irkkan C, Morrison C, Croce CM, Shapiro CL, Huebner K. micro-
RNA expression profiling identifies a four microRNA signature as a 
novel diagnostic and prognostic biomarker in triple negative breast 
cancers. Oncotarget 2014; 5: 1174-1184 [PMID: 24632568 DOI: 
10.18632/oncotarget.1682]
96 Yan W, Li R, Liu Y, Yang P, Wang Z, Zhang C, Bao Z, Zhang W, 
You Y, Jiang T. MicroRNA expression patterns in the malignant 
progression of gliomas and a 5-microRNA signature for prognosis. 
Oncotarget 2014; 5: 12908-12915 [PMID: 25415048 DOI: 
10.18632/oncotarget.2679]
97 Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, 
Fernandez AF, Davalos V, Villanueva A, Montoya G, Yamamoto 
H, Schwartz S, Esteller M. A genetic defect in exportin-5 traps 
precursor microRNAs in the nucleus of cancer cells. Cancer 
Cell 2010; 18: 303-315 [PMID: 20951941 DOI: 10.1016/j.ccr. 
2010.09.007]
98 Ziebarth JD, Bhattacharya A, Cui Y. Integrative analysis of 
somatic mutations altering microRNA targeting in cancer genomes. 
PLoS One 2012; 7: e47137 [PMID: 23091610 DOI: 10.1371/
journal.pone.0047137]
99 Sun G, Yan J, Noltner K, Feng J, Li H, Sarkis DA, Sommer SS, 
Rossi JJ. SNPs in human miRNA genes affect biogenesis and 
function. RNA 2009; 15: 1640-1651 [PMID: 19617315 DOI: 
10.1261/rna.1560209]
100 Svoronos AA, Engelman DM, Slack FJ. OncomiR or Tumor 
Suppressor? The Duplicity of MicroRNAs in Cancer. Cancer Res 
2016; 76: 3666-3670 [PMID: 27325641 DOI: 10.1158/0008-5472.
CAN-16-0359]
101 Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu 
M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, 
Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. miR-15 and 
miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci 
USA 2005; 102: 13944-13949 [PMID: 16166262 DOI: 10.1073/
pnas.0506654102]
102 Pekarsky Y, Croce CM. Role of miR-15/16 in CLL. Cell Death 
Differ 2015; 22: 6-11 [PMID: 24971479 DOI: 10.1038/cdd.2014.87]
103 Reid G. MicroRNAs in mesothelioma: from tumour suppressors 
and biomarkers to therapeutic targets. J Thorac Dis 2015; 7: 
1031-1040 [PMID: 26150916 DOI: 10.3978/j.issn.2072-1439.2015.
04.56]
104 Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in 
cancer: discovery, function and future perspectives. Cell Death 
Differ 2010; 17: 215-220 [PMID: 19498445 DOI: 10.1038/
cdd.2009.69]
105 Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos 
P, Petrelli NJ, Dunn SP, Krueger LJ. MicroRNA let-7a down-
regulates MYC and reverts MYC-induced growth in Burkitt 
lymphoma cells. Cancer Res 2007; 67: 9762-9770 [PMID: 
17942906 DOI: 10.1158/0008-5472.CAN-07-2462]
106 Wang X, Cao L, Wang Y, Wang X, Liu N, You Y. Regulation 
of let-7 and its target oncogenes (Review). Oncol Lett 2012; 3: 
955-960 [PMID: 22783372 DOI: 10.3892/ol.2012.609]
107 Liu ZL, Wang H, Liu J, Wang ZX. MicroRNA-21 (miR-21) 
expression promotes growth, metastasis, and chemo- or radio-
resistance in non-small cell lung cancer cells by targeting PTEN. 
Mol Cell Biochem 2013; 372: 35-45 [PMID: 22956424 DOI: 
10.1007/s11010-012-1443-3]
108 Sandhu SK, Fassan M, Volinia S, Lovat F, Balatti V, Pekarsky 
Y, Croce CM. B-cell malignancies in microRNA Eμ-miR-17~92 
transgenic mice. Proc Natl Acad Sci USA 2013; 110: 18208-18213 
[PMID: 24145403 DOI: 10.1073/pnas.1315365110]
109 Mavrakis KJ, Van Der Meulen J, Wolfe AL, Liu X, Mets E, Taghon 
T, Khan AA, Setty M, Rondou P, Vandenberghe P, Delabesse E, 
Benoit Y, Socci NB, Leslie CS, Van Vlierberghe P, Speleman F, 
Wendel HG. A cooperative microRNA-tumor suppressor gene 
network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet 
2011; 43: 673-678 [PMID: 21642990 DOI: 10.1038/ng.858]
110 Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, 
Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo 
JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli 
P, Negrini M, Croce CM. MicroRNA gene expression deregulation 
in human breast cancer. Cancer Res 2005; 65: 7065-7070 [PMID: 
16103053 DOI: 10.1158/0008-5472.CAN-05-1783]
111 Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, 
Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, 
Calin GA, Croce CM, Harris CC. MicroRNA expression profiles 
associated with prognosis and therapeutic outcome in colon adeno-
carcinoma. JAMA 2008; 299: 425-436 [PMID: 18230780 DOI: 
10.1001/jama.299.4.425]
112 Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, 
Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, 
Jaenisch R, Sharp PA, Jacks T. Targeted deletion reveals essential 
and overlapping functions of the miR-17 through 92 family of 
miRNA clusters. Cell 2008; 132: 875-886 [PMID: 18329372 DOI: 
10.1016/j.cell.2008.02.019]
113 Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H, Liu Z. MicroRNA-
10b promotes migration and invasion through KLF4 in human 
esophageal cancer cell lines. J Biol Chem 2010; 285: 7986-7994 
[PMID: 20075075 DOI: 10.1074/jbc.M109.062877]
114 Wang CZ, Yuan P, Li Y. MiR-126 regulated breast cancer cell 
invasion by targeting ADAM9. Int J Clin Exp Pathol 2015; 8: 
6547-6553 [PMID: 26261534]
115 Gong M, Ma J, Guillemette R, Zhou M, Yang Y, Yang Y, Hock JM, 
Yu X. miR-335 inhibits small cell lung cancer bone metastases via 
IGF-IR and RANKL pathways. Mol Cancer Res 2014; 12: 101-110 
[PMID: 23966614 DOI: 10.1158/1541-7786.MCR-13-0136]
116 Rokavec M, Li H, Jiang L, Hermeking H. The p53/miR-34 axis in 
development and disease. J Mol Cell Biol 2014; 6: 214-230 [PMID: 
24815299 DOI: 10.1093/jmcb/mju003]
117 Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X. miR-34a inhibits 
migration and invasion by down-regulation of c-Met expression 
in human hepatocellular carcinoma cells. Cancer Lett 2009; 275: 
44-53 [PMID: 19006648 DOI: 10.1016/j.canlet.2008.09.035]
Oliveto S et al . miRNAs in translation regulation and cancer
56 February 26, 2017|Volume 8|Issue 1|WJBC|www.wjgnet.com
118 Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman 
WM, Slack FJ. Nanoparticle-based therapy in an in vivo 
microRNA-155 (miR-155)-dependent mouse model of lymphoma. 
Proc Natl Acad Sci USA 2012; 109: E1695-E1704 [PMID: 
22685206 DOI: 10.1073/pnas.1201516109]
119 Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, 
Cheng JQ. MicroRNA-155 regulates cell survival, growth, and 
chemosensitivity by targeting FOXO3a in breast cancer. J Biol 
Chem 2010; 285: 17869-17879 [PMID: 20371610 DOI: 10.1074/
jbc.M110.101055]
120 Levati L, Pagani E, Romani S, Castiglia D, Piccinni E, Covaciu 
C, Caporaso P, Bondanza S, Antonetti FR, Bonmassar E, Martelli 
F, Alvino E, D’Atri S. MicroRNA-155 targets the SKI gene in 
human melanoma cell lines. Pigment Cell Melanoma Res 2011; 24: 
538-550 [PMID: 21466664 DOI: 10.1111/j.1755-148X.2011.00857.x]
121 Li CL, Nie H, Wang M, Su LP, Li JF, Yu YY, Yan M, Qu QL, 
Zhu ZG, Liu BY. microRNA-155 is downregulated in gastric 
cancer cells and involved in cell metastasis. Oncol Rep 2012; 27: 
1960-1966 [PMID: 22426647 DOI: 10.3892/or.2012.1719]
122 Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. MiR-125 
in normal and malignant hematopoiesis. Leukemia 2012; 26: 
2011-2018 [PMID: 22456625 DOI: 10.1038/leu.2012.90]
123 Sun YM, Lin KY, Chen YQ. Diverse functions of miR-125 family 
in different cell contexts. J Hematol Oncol 2013; 6: 6 [PMID: 
23321005 DOI: 10.1186/1756-8722-6-6]
124 Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu 
Rev Med 2009; 60: 167-179 [PMID: 19630570 DOI: 10.1146/
annurev.med.59.053006.104707]
125 Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, 
recent applications, and next frontiers. Mutat Res 2011; 717: 1-8 
[PMID: 21458467 DOI: 10.1016/j.mrfmmm.2011.03.009]
126 Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular 
bodies associate with components of miRNA effector complexes 
and modulate miRNA activity. Nat Cell Biol 2009; 11: 1143-1149 
[PMID: 19684575 DOI: 10.1038/ncb1929]
127 Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular orga-
nelles important in intercellular communication. J Proteomics 
2010; 73: 1907-1920 [PMID: 20601276 DOI: 10.1016/j.jprot. 
2010.06.006]
128 Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-
Bengtson B, Dingli F, Loew D, Tkach M, Théry C. Proteomic 
comparison defines novel markers to characterize heterogeneous 
populations of extracellular vesicle subtypes. Proc Natl Acad Sci 
USA 2016; 113: E968-E977 [PMID: 26858453 DOI: 10.1073/
pnas.1521230113]
129 Minciacchi VR, Freeman MR, Di Vizio D. Extracellular vesicles 
in cancer: exosomes, microvesicles and the emerging role of 
large oncosomes. Semin Cell Dev Biol 2015; 40: 41-51 [PMID: 
25721812 DOI: 10.1016/j.semcdb.2015.02.010]
130 Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu 
Y, Chow A, O’Connor ST, Chin AR, Yen Y, Wang Y, Marcusson 
EG, Chu P, Wu J, Wu X, Li AX, Li Z, Gao H, Ren X, Boldin MP, 
Lin PC, Wang SE. Cancer-secreted miR-105 destroys vascular 
endothelial barriers to promote metastasis. Cancer Cell 2014; 25: 
501-515 [PMID: 24735924 DOI: 10.1016/j.ccr.2014.03.007]
131 Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam 
R, Lovat F, Fadda P, Mao C, Nuovo GJ, Zanesi N, Crawford M, 
Ozer GH, Wernicke D, Alder H, Caligiuri MA, Nana-Sinkam P, 
Perrotti D, Croce CM. MicroRNAs bind to Toll-like receptors to 
induce prometastatic inflammatory response. Proc Natl Acad Sci 
USA 2012; 109: E2110-E2116 [PMID: 22753494 DOI: 10.1073/
pnas.1209414109]
132 Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery 
CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, 
Clark KR, Mendell JR, Mendell JT. Therapeutic microRNA 
delivery suppresses tumorigenesis in a murine liver cancer model. 
Cell 2009; 137: 1005-1017 [PMID: 19524505 DOI: 10.1016/
j.cell.2009.04.021]
133 Hou X, Zhang M, Qiao H. Diagnostic significance of miR-106a in 
gastric cancer. Int J Clin Exp Pathol 2015; 8: 13096-13101 [PMID: 
26722506]
134 Nagpal N, Ahmad HM, Chameettachal S, Sundar D, Ghosh S, 
Kulshreshtha R. HIF-inducible miR-191 promotes migration in 
breast cancer through complex regulation of TGFβ-signaling 
in hypoxic microenvironment. Sci Rep 2015; 5: 9650 [PMID: 
25867965 DOI: 10.1038/srep09650]
135 Zhang XF, Li KK, Gao L, Li SZ, Chen K, Zhang JB, Wang D, Tu 
RF, Zhang JX, Tao KX, Wang G, Zhang XD. miR-191 promotes 
tumorigenesis of human colorectal cancer through targeting C/
EBPβ. Oncotarget 2015; 6: 4144-4158 [PMID: 25784653 DOI: 
10.18632/oncotarget.2864]
136 Muniyappa MK, Dowling P, Henry M, Meleady P, Doolan P, 
Gammell P, Clynes M, Barron N. MiRNA-29a regulates the ex-
pression of numerous proteins and reduces the invasiveness and 
proliferation of human carcinoma cell lines. Eur J Cancer 2009; 45: 
3104-3118 [PMID: 19818597 DOI: 10.1016/j.ejca.2009.09.014]
137 Guo Y, Fu W, Chen H, Shang C, Zhong M. miR-24 functions as a 
tumor suppressor in Hep2 laryngeal carcinoma cells partly through 
down-regulation of the S100A8 protein. Oncol Rep 2012; 27: 
1097-1103 [PMID: 22139384 DOI: 10.3892/or.2011.1571]
138 Zhao G, Liu L, Zhao T, Jin S, Jiang S, Cao S, Han J, Xin Y, Dong Q, 
Liu X, Cui J. Upregulation of miR-24 promotes cell proliferation 
by targeting NAIF1 in non-small cell lung cancer. Tumour Biol 
2015; 36: 3693-3701 [PMID: 25725584 DOI: 10.1007/s13277- 
014-3008-4]
139 Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. 
miR221/222 in cancer: their role in tumor progression and response 
to therapy. Curr Mol Med 2012; 12: 27-33 [PMID: 22082479]
P- Reviewer: Bai G, Witzany G    S- Editor: Kong JX    L- Editor: A 
E- Editor: Li D 
Oliveto S et al . miRNAs in translation regulation and cancer
© 2017 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
